<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063734</url>
  </required_header>
  <id_info>
    <org_study_id>THR-687-002</org_study_id>
    <secondary_id>2020-000362-42</secondary_id>
    <nct_id>NCT05063734</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.</brief_title>
  <acronym>INTEGRAL</acronym>
  <official_title>A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-687 Injections and to Evaluate the Efficacy and Safety of THR-687 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxurion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxurion</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to select the THR-687 dose level (Part A of the study) and to assess&#xD;
      the efficacy and safety of the selected dose level compared to aflibercept (Part B of the&#xD;
      study).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in BCVA ETDRS letter score, at Month 3, in treatment-naïve subjects in Part B of the study</measure>
    <time_frame>At Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weighted average of the change from Baseline in BCVA ETDRS letter score from Day 8 through Month 3 using the trapezoidal rule (AUC), in treatment-naïve subjects in Part B of the study</measure>
    <time_frame>at Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BCVA ETDRS letter score, by study visit, in treatment-naïve subjects in Part B of the study</measure>
    <time_frame>Up to Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Central Subfield Thickness (CST), based on Spectral Domain Optical Coherence Tomography (SD-OCT), as assessed by the Central Reading Center (CRC), by study visit, in treatment-naïve subjects in Part B of the study</measure>
    <time_frame>Up to Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to Month 8</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">303</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Part A, THR-687 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, THR-687 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, treatment naïve subjects, THR-687 selected dose level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, treatment naïve subjects, aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, previously treated subjects, THR-687 selected dose level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, previously treated subjects, aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-687 dose level 1</intervention_name>
    <description>3 intravitreal injections of THR-687 dose level 1, 1 month apart</description>
    <arm_group_label>Part A, THR-687 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-687 dose level 2</intervention_name>
    <description>3 intravitreal injections of THR-687 dose level 2, 1 month apart</description>
    <arm_group_label>Part A, THR-687 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-687 selected dose level</intervention_name>
    <description>3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.</description>
    <arm_group_label>Part B, previously treated subjects, THR-687 selected dose level</arm_group_label>
    <arm_group_label>Part B, treatment naïve subjects, THR-687 selected dose level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.</description>
    <arm_group_label>Part B, previously treated subjects, aflibercept</arm_group_label>
    <arm_group_label>Part B, treatment naïve subjects, aflibercept</arm_group_label>
    <other_name>Eylea®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The subjects in this study will be subjects with central-involved DME (CI-DME). Both&#xD;
        treatment-naïve and previously treated subjects will be included.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the subject prior to screening procedures&#xD;
&#xD;
          -  Male or female aged 18 years or older at the time of signing the informed consent&#xD;
&#xD;
          -  Type 1 or type 2 diabetes&#xD;
&#xD;
          -  BCVA ETDRS letter score ≥ 39 in the study eye&#xD;
&#xD;
          -  CI-DME with CST of ≥ 300µm in men (or equivalent in women), measured from RPE to ILM&#xD;
             inclusively, on SD-OCT, in the study eye&#xD;
&#xD;
          -  BCVA ETDRS letter score ≥ 34 in the fellow eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular edema due to causes other than DME in the study eye&#xD;
&#xD;
          -  Concurrent disease in the study eye, other than DME, that could require medical or&#xD;
             surgical intervention during the study period or could confound interpretation of the&#xD;
             results&#xD;
&#xD;
          -  Any condition in the study eye that could confound the ability to detect the efficacy&#xD;
             of the investigational medicinal product&#xD;
&#xD;
          -  Previous confounding medications / interventions, or their planned administration&#xD;
             during the study&#xD;
&#xD;
          -  Presence of iris neovascularisation in the study eye&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye&#xD;
&#xD;
          -  Previously received THR-687 or any other experimental therapy for DME, in either eye&#xD;
&#xD;
          -  Any active or suspected ocular or periocular infection, or active intraocular&#xD;
             inflammation, in either eye&#xD;
&#xD;
          -  Untreated Diabetes&#xD;
&#xD;
          -  Glycated haemoglobin A (HbA1c) &gt; 12%&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Oxurion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Development</last_name>
    <phone>+32 (0)16 751 310</phone>
    <email>info@oxurion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Salehi Retina Institute Inc.</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Eye Specialists Medical Group, Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Southern Colorado, P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates, Ltd</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Retina and macula Associates, PC</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell health Laboratories</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Surgeons of Central New York, PC</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulsa Retina Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Research Center of Retina</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, P.A.</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Center of Texas</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

